生命科学资讯
生物技术与制药领域的最新动态
Kyowa Kirin reveals side effect in trial; GSK was lone bidder for RAPT
FDA rejects Aquestive's allergy drug over packaging issues
FDA opens submissions for PreCheck program to speed up US factory builds
SanegeneBio licenses RNAi candidate to Genentech for $200M upfront
Pharming公司免疫缺陷药物获CRL，不适用于年轻患者。
Pharming’s immunodeficiency drug gets CRL for use in younger patients
欧洲法律变更意味着制药商可能更早面临仿制药竞争
European law changes mean drugmakers may have to grapple with generic competition sooner
大型药企财报季拉开序幕；第三轮IRA药品名单出炉；恒瑞医药迎来突破性时刻；更多行业动态。
Big Pharma earnings kick off; Third-round IRA drugs selected; Hengrui’s trailblazing moment; and more
FDA称已就Corcept被拒库欣综合征药物问题早期做出解释。
FDA says it explained issues early on for Corcept's rejected Cushing's syndrome drug
Bitterroot回归临床前生物技术领域，专注CD47靶点，同时CEO离职。
Bitterroot reverts to preclinical biotech in CD47 as CEO leaves
欧洲药品管理局人用药品委员会反对礼来Mounjaro用于心衰治疗，支持诺和诺德Kayshild。
CHMP opposes Lilly’s Mounjaro in heart failure, backs Novo’s Kayshild
Ultragenyx就罕见神经疾病基因疗法向FDA重新提交申请。
Ultragenyx resubmits gene therapy for rare neuro disease to FDA
Quince罕见病激素疗法失败，股价暴跌
Quince's steroid therapy for rare disease fails, shares tank
Janux任命首席营销官，此前与百时美施贵宝达成T细胞衔接器协议；Lexeo一批新任命出炉
Janux hires CMO after T cell engager deal with Bristol Myers; A batch of appointments at Lexeo
里德·乔布斯的癌症生物技术投资公司Yosemite瞄准3.5亿美元基金
Reed Jobs' cancer biotech investment firm Yosemite eyes $350M fund
阿斯利康以12亿美元收购石药集团长效减肥药。
AstraZeneca pays $1.2B for CSPC's long-acting obesity drugs
武田制药"预期"其畅销药Entyvio将进入医保谈判。
Takeda 'anticipated' Medicare negotiations for top seller Entyvio
武田制药候任CEO表示，不赞成特朗普的最惠国待遇协议。
Takeda is ‘not in favor’ of Trump’s MFN deals, CEO-designate says
白宫推迟原定特朗普处方药计划发布会
White House postpones planned TrumpRx launch event
赛诺菲疫苗业务受挫，誓言坚守承诺不动摇。
Sanofi vows to stay committed to vaccines as portfolio takes a hit